-
"Divine Magazine" CA heavy review: ADC's status quo, challenges, opportunities and future
Time of Update: 2022-08-15
HER2-positive breast cancer , HER2-positive gastric cancer , triple-negative breast cancer, urothelial cancer , cervical cancer Antitumor activity of ADCsAntitumor activity of ADCs To date, the expression of HER2, Trop-2, nectin-4, and a variety of other antigens have been described in multiple tumor types, leading to the hypothesis that ADCs targeting these antigens could achieve broad -spectrum implementation in solid tumors.
-
Express creates multiple firsts!
Time of Update: 2022-08-15
Today, Caribou Biosciences announced that its CRISPR-based gene editing-engineered ready-to-use CAR-T therapy CB-010 has achieved positive results in a Phase 1 clinical trial in patients with relapsed/refractory B-cell non-Hodgkin lymphoma .
-
Overview of Drug Administration Policies "The 14th Five-Year Plan for Drug Supervision Network Security and Informatization Construction" issued
Time of Update: 2022-08-15
Recently, the State Food and Drug Administration issued the "14th Five-Year Plan for Drug Regulatory Network Security and Informatization Construction" . The "Plan" is formulated in accordance with t
-
U.S. House of Representatives officials question FDA!
Time of Update: 2022-08-15
Califf, questioning Chinese companies using data from clinical trials conducted in/mainly in China to submit new drugs apply .
Califf, questioning Chinese companies using data from clinical trials conducted in/mainly in China to submit new drugs apply .
-
The profit is super Hengrui!
Time of Update: 2022-08-15
In 2020, thanks to the sales of new crown nucleic acid detection reagents, Mingde Bio achieved revenue of 959 million yuan, a year-on-year increase of 429.
In 2020, thanks to the sales of new crown nucleic acid detection reagents, Mingde Bio achieved revenue of 959 million yuan, a year-on-year increase of 429.
-
AI Pharma, a gimmick or the future?
Time of Update: 2022-08-15
Gimmick, or the future? This is a question that everyone often asks in the face of AI pharmaceuticals, but it is not a problem faced by AI pharmaceuticals . The DeepMind team hit the industry with an
-
The mRNA new crown vaccine competition is in full swing, and more than 10 domestic pharmaceutical companies are deployed!
Time of Update: 2022-08-15
Currently on the new crown mRNA vaccine track in China, Watson Bio-Aibo Bio, Sri Lanka Microbiology, Aimei Vaccine, Ribo Bio-Agena Bio, Sinopharm Zhongsheng Fu Nuojian, Ruikeji Bio, Westin Bio, Companies such as CanSino, CSPC, and Lanque Biological are all making rapid progress .
-
Shortage of medicines, urgent clinical needs, medicines for children!
Time of Update: 2022-08-15
Proposed indications (or functional indications): From: CDE official website Stiripentol received orphan drug designation in the European Union in 2001, followed by approval in the European Union in 2007 and in Japan and Canada in 2012 in combination with clobazam and valproate for severe myoclonus in infancy Adjuvant treatment of refractory generalized tonic-clonic seizures in patients with epilepsy (SMEI, Dravet syndrome) .
-
Roche's TIGIT monoclonal antibody has failed again, and a large number of domestic biopharmaceutical companies have been deployed. Who can become famous in one battle?
Time of Update: 2022-08-15
Source: Roche official website In fact, as early as March 30, 2022, Roche issued a press release, pointing out that the phase III pivotal SKYSCRAPER-02 trial of its immunotherapy drug tiragolumab, with Roche FDA-approved PD-L1 inhibitor Tecentriq (atezolizumab), carboplatin In combination with etoposide chemotherapy, its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) have not been met in 490 patients with extensively advanced small cell lung cancer (ES-SCLC) .
-
What new developments are worth paying attention to at the opening of the gene and cell therapy industry conference today?
Time of Update: 2022-08-15
Retrieved May 16, 2022, from https:// upcoming-american-society-of-gene-and-cell-therapys-25th-annual-meeting/ [3] A First-in-Human Phase 1 Clinical Gene Therapy Trial for the Treatment of Heart Failure Using a Novel Re-Engineered Adeno-Associated Vector.
-
Break through the dark hour!
Time of Update: 2022-08-15
Activate the start buttonActivate the start button Accelerate the recovery of Shanghai pharmaceutical companies' production capacity From the "white list" of the first batch of key enterprises to resume work and production, it is not difficult to find that the epidemic prevention guarantee covers the entire anti-epidemic industry chain, including the production and supplier enterprises of anti-epidemic materials such as masks and protective clothing, drug manufacturers, third-party nucleic acid testing, Vaccine production and research and development institutions and enterprises, etc.
-
The first phase of the live broadcast preview of pharmaceutical innovation talks to explore new opportunities for cross-border integration of multi-omics technology and pharmaceutical innovation
Time of Update: 2022-08-15
, Ltd. were the keynote speakers Hu Zhibin, Deputy Secretary of the Party Committee and President of Nanjing Medical University, and Zhang Wei, Chief Technology Officer of Jiangsu Pinsheng Medical Technology Group Co.
-
$157 million: AstraZeneca brings in early-stage Covid-19 drug
Time of Update: 2022-08-15
AstraZeneca will pay up to US$157 million to obtain an exclusive global license for this drug On May 17, AstraZeneca announced a partnership with RQ Biotechnology to introduce an early-stage novel coronavirus monoclonal antibody.
-
The Bricks of Other Mountains: The Supply of More than 2,500 Generic Drugs in Japan Is Seriously Insufficient
Time of Update: 2022-08-15
Generic drug manufacturers are more inclined to expand their competitive advantage by increasing the variety of products, In response to the current shortage, Japan's Ministry of Health, Labour and Welfare has asked manufacturers to increase production.
-
Eli Lilly's CDK4/6 inhibitor Verzenios gets MHRA approval for early breast cancer
Time of Update: 2022-08-15
Eli Lilly's Verzenios (abemaciclib) has received marketing authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the adjuvant treatment of Verzenios in combination with endocrine therapy for HR+, HER2-, high-risk node-positive early breast cancer (EBC) patients .
-
First and only drug for primary IgA nephropathy approved in Europe
Time of Update: 2022-08-15
Recently, Calliditas Therapeutics announced that the European Commission (EC) has granted a conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin in adults at risk of rapid disease progression and with a urine protein-to-creatinine ratio (UPCR) ≥1.
-
Kanglong Chemical's performance has "greatly changed", and the domestic CXO industry may enter a bottleneck period of development
Time of Update: 2022-08-15
Driven by many factors such as overseas order transfer, strong domestic demand for innovative drug research and development, expansion of the pharmaceutical market, and government preferential policies, the growth rate of China's CXO market has exceeded that of the global market in the past five years .
-
Innovative drug investment in the cold winter: finding certainty from uncertainty
Time of Update: 2022-08-15
Return to the simplest logic of innovative drugsReturn to the simplest logic of innovative drugs At this point, I am afraid that the first-tier investors will complain: I don’t want to invest in those new topics, I really want to invest in small molecules and large molecules with higher certainty, but the low-risk targets are too strong, and the ones that are not.
-
Facing Omikron, where is the next "special medicine"?
Time of Update: 2022-08-15
The production of cytokine storm in human peripheral blood mononuclear cells (PBMCs) induced by SARS-CoV-2-Omicron, suggesting that orebatinib has the potential to treat novel coronavirus pneumonia (COVID-19) Especially the potential of moderate to severe patients Not long ago, on May 18, 2022, a preclinical study at the Hutchinson Cancer Research Center showed that Ponatinib's same-target drug orebatinib (Neric®, olverembatinib) can effectively inhibit the new coronavirus variant virus.
-
Life and death speed!
Time of Update: 2022-08-15
，、，。~5200（~1000）、，，、、、、、、，，，。，、， 20161123，【】solanezumab， 2018214，！APECS。Verubecestat（MK-8931） 2019130，！ 2019322，！(Biogen)。！ On May 10th, local time in the United States, Endpoints News, a well-known
